On July 24, 2020, President Trump signed Executive Order 13938 directing the Department of Health and Human Services to establish a program permitting the importation of FDA-approved drugs from Canada and other countries at lower prices. The order instructed HHS to create a Safe Importation Action Plan within 30 days, representing an attempt to address prescription drug costs through regulatory action rather than legislative reform. However, by early 2021, HHS had not implemented a functional importation program despite issuing policy guidance. The executive order remained largely symbolic, with no operational mechanism created to allow Americans to actually purchase imported medications.

The intended beneficiaries of this order were American patients struggling with high prescription drug costs, particularly those without adequate insurance coverage or facing out-of-pocket expenses. By enabling importation of identical medications available at lower prices in Canada and other developed nations, the administration sought to leverage price differentials to reduce the financial burden on individual consumers. The practical effect, however, was minimal due to the lack of implementation, leaving patients without the promised relief.

This action occurred within a broader healthcare policy landscape marked by inconsistency and regulatory dysfunction. While the drug importation order appeared to prioritize patient access and affordability, other Trump administration healthcare actions moved in opposite directions. The FDA's authorization of fruit-flavored vapes, the restriction of mifepristone access via telehealth, and the administration's overhaul of CDC vaccine recommendations all reflected a pattern of deregulation and reduced access to health interventions, albeit in different areas. The unfulfilled drug importation executive order thus represents not a genuine commitment to healthcare accessibility but rather symbolic action that failed to translate into concrete policy implementation.

The order's incomplete execution illustrates a recurring gap between Trump administration healthcare pronouncements and actual implementation. Without legislative backing or dedicated funding, and facing entrenched pharmaceutical industry interests, the executive order's directive proved insufficient to overcome institutional barriers. The promised Safe Importation Action Plan never became operational, leaving patients with unmet expectations and no actual mechanism to access lower-cost medications, underscoring the limitations of executive action without sustained bureaucratic follow-through.